36 results on '"Tilly, H."'
Search Results
2. Dose dance in lymphomas.
3. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
4. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment andfollow-up†.
5. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
6. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
7. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
8. Manifestations dysimmunitaires associées aux lymphomes
9. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
10. Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.
11. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
12. 623MO Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients.
13. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
14. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party†.
15. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
16. 1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors.
17. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
18. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.
19. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
20. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).
21. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.
22. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
23. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
24. Transient anti rhesus alloantibody produced by graft after non-myeloablative allogeneic stem cell transplant
25. 266 - Impact of Cytogenetics on Outcome after Allogeneic Transplantation for Myelodysplastic Syndrome or Post MDS Secundary Myeloid Leukemia.
26. 265 - Prognostic Value of Lymphocyte-Monocyte Ratio in Primary Myelodysplastic Syndrome.
27. La kinésithérapie est-elle toujours la pierre angulaire du traitement ?
28. Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib.
29. 125 FEBRILE EPISODES IN PATIENTS WITH MDS TREATED WITH AZACITIDINE. A THREE YEAR MONOCENTRIC RETROSPECTIVE STUDY.
30. Comparison Between Short Course (Single Fraction) and Long Course (Multiple Fractions) on Pain Relief in Patients With Bone Localization of Multiple Myeloma.
31. P-077 Cytogenetic contribution in the diagnosis of chronic cytopenias without dysplasia.
32. 282 Familial myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): Report of 2 families
33. 323 Prognostic impact of cytogenetics in a series of 560 patients with myelodysplastic syndrome in a single institution
34. C001 Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes
35. P115 Prognostic factors in chronic myelomonocytic leukaemia: a retrospective analysis of 113 patients
36. P096 AML/MDS with chromosome 5 and 7 abnormalities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.